Hepatocellular Carcinoma: Diagnosis and Treatment (Current Clinical Oncology)

* Hepatocellular carcinoma (HCC) used to be regarded as a rare disease. However, the increasing numbers of chronic HCC carriers in the U.S. and subsequent increased incidences of HCC seen in most large medical centers means that it is no longer an uncommon disease for gastroenterologists or oncologists to encounter and its incidence and epidemiology are changing. During this exciting time in the field of HCC basic science and clinical management, many changes are simultaneously occurring at multiple levels of our understanding and management of the disease. Suddenly, there are several new choices of therapy to offer patients. Hepatocellular Carcinoma, 3rd edition addresses this fast-changing disease and gives the reader a clearer understanding of the many mechanisms involved in carcinogenesis of the liver. This comprehensive and detailed review of how to diagnose and treat hepatocellular carcinoma is written by international leaders in the field, covering both clinical treatment choices and the basic science underlying HCC development. Updated and enhanced from the last edition in 2009, Hepatocellular Carcinoma, 3rd edition features 12 new chapters including discussion of molecular markers, molecular hepatocarcinogenesis, microenvironment, heterogeneity, the new and exciting contributions of immunotherapy, and updates on the major effective hepatitis therapies that will transform HCC incidence and perhaps also the therapy. This cutting-edge text is a vital resource and must-have for today's hepatologists and medical and surgical oncologists. "This is a well written text and should be a good reference book for those who see patients with HCC.." - Practical Gastroenterology "...a useful tool for both physicians and surgeons with a specific interest in the management of patients with HCC." - Digestive and Liver Disease

Dr. Brian I. Carr is Professor of Medical Oncology, Thomas Jefferson University, Philadelphia and Professor, IRCCS de Bellis, National Institute for Digestive Diseases, Castellana Grotte (BA), Italy. Since 1977 he has devoted both his clinical activities and research science efforts to the clinical and scientific study of primary liver cancer (HCC or hepatocellular carcinoma). He has published more than 250 papers in peer-reviewed journals, over 350 abstracts and given a similar number of meeting presentations, written chapters in 36 books and edited 2 books. He is guest editor for the HCC special issue of Seminars in Oncology, Aug, 2012 and has written the chapter on HCC for the last 2 editions of Harrison’s Internal Medicine.